Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

被引：3
|
作者：
Agrawal, Vaibhav [1 ]
Croslin, Cindy [1 ]
Beltran, Asuscena L. [1 ]
Zhang, Jianying [2 ]
Palmer, Joycelynne [3 ]
Quy Huynh-Tran [1 ]
Hernandez, Rochelle [1 ]
Thomas, Sandra [4 ]
Robbins, Marjorie [4 ]
Aribi, Ahmed [1 ]
Ali, Haris [1 ]
Stein, Anthony S. [1 ]
Budde, Elizabeth L. [1 ]
Al Malki, Monzr M. [1 ]
Marcucci, Guido [1 ]
机构：
[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Computat & Quantitat Med BRI, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Beckman Res Inst, Dept Computat & Quantitat Med, Duarte, CA USA
[4] City Hope Natl Med Ctr, Dept Clin & Translat Project Dev, Duarte, CA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165894
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6235 / 6236
页数：2
相关论文
共 50 条
  • [1] Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Sandhu, Karamjeet S.
    Quy Huynh-Tran
    Cooper, Elise Elise
    Zhang, Jianying
    Palmer, Joycelynne
    Tsai, Ni-Chun
    Thomas, Sandra
    Robbins, Marjorie
    Aribi, Ahmed
    Salhotra, Amandeep
    Mei, Mathew
    Cai, Ji-Lian
    Spielberger, Ricardo
    Koller, Paul
    Aldoss, Ibrahim
    Stein, Anthony
    Marcucci, Guido
    Budde, L. Elizabeth
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S276 - S276
  • [2] Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
    Daver, Naval
    Lee, Kyoo Hyung
    Choi, Yunsuk
    Jonas, Brian A.
    Arellano, Martha
    Koller, Paul B.
    Jung, Chul W.
    Sohn, Sang Kyun
    Fathi, Amir T.
    Lee, Jeong-Ok
    Yoon, Sung-Soo
    Watts, Justin M.
    Vachhani, Pankit
    Shin, Ho-Jin
    Hu, Jia
    Sinha, Ranjeet
    Khan, Nawazish
    Rice, William G.
    Bejar, Rafael
    [J]. BLOOD, 2023, 142
  • [3] A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
    Cashen, Amanda F.
    Liu, Hongtao
    Al Malki, Monzr M.
    Zeidner, Joshua F.
    Foster, Matthew C.
    Pannunzio, Angela
    Ramsey, Brett
    Baughman, Jan
    Muth, John
    Bakkacha, Ouiam
    McNulty, Eileen
    Jacobs, Kenneth
    Davidson-Moncada, Jan K.
    Wei, Andrew H.
    [J]. BLOOD, 2022, 140 : 12740 - 12741
  • [4] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    [J]. BLOOD, 2021, 138
  • [5] Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Cortes, Jorge E.
    Ganguly, Siddhartha
    Kraemer, Alwin
    Levis, Mark J.
    Martinelli, Giovanni
    Perl, Alexander E.
    Russell, Nigel H.
    Choi, Youngsook
    Mendell, Jeanne
    Namuyinga, Ruth
    Hoang Pham
    Said, Nabil
    Wang, Yibin
    Mitov, Tsvetomir
    Kim, Ben
    Khaled, Samer K.
    [J]. BLOOD, 2019, 134
  • [6] TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF ALRIZOMADLIN (APG-115), ALONE OR COMBINED WITH 5-AZACITIDINE, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)
    Zhai, Yifan
    Kadia, Tapan
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A474 - A474
  • [7] Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
    Jaeger, Ulrich
    Worel, Nina
    McGuirk, Joseph P.
    Riedell, Peter A.
    Fleury, Isabelle
    Du, Yan
    Han, Xia
    Pearson, David
    Redondo, Santiago
    Waller, Edmund K.
    [J]. BLOOD ADVANCES, 2023, 7 (11) : 2283 - 2286
  • [8] Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML)
    Erba, Harry Paul
    Becker, Pamela S.
    Shami, Paul J.
    Grunwald, Michael Richard
    Flesher, Donna L.
    Zhang, Yilong
    Rasmussen, Erik
    Henary, Haby A.
    Wang, Eunice S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Daver, Naval
    Boddu, Prajwal
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    DiNardo, Courtney
    Konopleva, Marina
    Pemmaraju, Naveen
    Kadia, Tapan
    Jain, Nitin
    Pierce, Sherry
    Hussain, Nawar
    Ning, Jing
    Nogueras-Gonzalez, Graciela
    Basu, Sreyashi
    Cortes, Jorge
    Sharma, Padmanee
    Kantarjian, Hagop
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S6 - S7
  • [10] A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
    Jonas, Brian A.
    Hou, Jing-Zhou
    Roboz, Gail J.
    Alvares, Caroline L.
    Jeyakumar, Deepa
    Edwards, John R.
    Erba, Harry P.
    Kelly, Richard J.
    Roellig, Christoph
    Fiedler, Walter
    Brackman, Deanna
    Siddani, Satya R.
    Chyla, Brenda
    Hilger-Rolfe, Jacqueline
    Watts, Justin M.
    [J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 743 - 752
12345